Legend has over 1,450 employees working in the US, and over 1,000 employees working across Europe.

Legend’s US manufacturing focuses on supporting US clinical trials and manufacturing commercial CAR-T therapies to patients across the United States, with CARVYKTI^® available as a treatment option in over 120+ treatment centers across America. Legend’s European manufacturing focuses on supporting clinical trial enrollment and treatment for European patients. Our collaboration with Johnson & Johnson expands our CARVYKTI^® manufacturing capabilities in both the US and Europe.

Our R&D operations are focused on pioneering novel cell therapies every day in the hope of changing treatment paradigms for incurable diseases. We are expanding our footprint in the US with the addition of a new state-of-the-art research facility in Philadelphia slated to open in 2025.